CeloNova BioSciences Release: New Treatment Option For Women An Alternative To Hysterectomy

SAN ANTONIO--(BUSINESS WIRE)--CeloNova BioSciences, Inc. today announced U.S. Food and Drug Administration (FDA) 510(k) clearance expanding the indication for their leading Embozene® microsphere product to include the treatment of uterine fibroids. This approval will give women suffering from uterine fibroids an important treatment option performed by interventional radiologists called uterine fibroid embolization (UFE).

Help employers find you! Check out all the jobs and post your resume.